About IRISS

IRISS received 501 c-6 designation from Internal Revenue Service (IRS) on March 7, 2012. The 501 c-6 designation recognizes IRISS Forum as a pharmaceutical industry trade organization, which provides a mechanism for IRISS to collaborate with other trade organizations within the pharmaceutical industry (ie PhRMA, DIA, RAPS, HL7) as well as global Health Authorities. IRISS represents a neutral forum for industry, vendors, health authorities, consultants, etc. to share information and work towards a standard method of implementing electronic submission specifications and improving interoperability of e-publishing tools, viewing tools, and systems.

IRISS Forum operates through a directorship structure, governed by an executive committee and board of directors.

Documents:

IRISS Operating Policy – August 2018
History of IRISS – February 2019

Board of Directors:

• Co-chairs
  • Karen Towns
  • Jake Doran
• Hans van Bruggen
• David Berglund
• Joakim Hindemith

Executive Committee:

• President / CEO: Kelly Hnat
• Vice President: Pending
• Treasurer: open

Steering Committee:

• Chair: Kelly Hnat (K2 Consulting)
• Topic Groups:
  • AdPromo: Doug Kent (Janssen – J&J Pharma)
  • China Regional: Jannie Ren (Pfizer)
  • CMC: Marie Parrish (Sun Pharma Advanced Research Company)
  • Digitalization in Regulatory: Cesar Vinces (Pfizer)
  • Electonic Product Information: Tris Nockles
  • GSO: David Ross (AstraZeneca)
  • IDMP (XEVMPD): Frits Stulp (Iperion)
• Website Liaison: Lenore Palma (Pharmaceutical eConsulting)
• Communications Team: Kelly Hnat

Page last updated: 20 May 2020